• 027044

    Characterization of protoporphyrin-IX-positive EVs following 5-ALA use in patients with malignant glioma


    Pamela Jones, Anudeep Yekula, Bob Carter, Leonora Balaj


    Introduction: Malignant gliomas are rapidly progressive brain tumors with high mortality. Fluorescence guided surgery (FGS) with 5-aminolevulinic acid (5-ALA) provides fluorescent delineation of malignant tissue, which helps achieve maximum safe resection. 5-ALA-based fluorescence is due to preferential accumulation of the fluorophore protoporphyrin-IX (PpIX) in malignant glioma tissue. Additionally, gliomas cells release extracellular vesicles (EVs) which carry biomarkers of disease.

    Objective: Our objectives were to first, determine if PpIX-positive EVs can be found from 5-ALA dosed Gli36 cells, determine if PpIX-positive EV signal can be detected up in plasma of glioma-bearing mice and not in control mice, and finally, to capture and enumerate PpIX-positive EVs from human plasma and correlate them as biomarkers of malignant glioma.

    Methods: We used imaging flow cytometry to characterize PpIX-positive EVs released from 5-ALA-dosed glioma cells, 5-ALA-dosed glioma-bearing xenograft models and control mice, as well as patients with malignant glioma undergoing 5-ALA FGS.

    Results: We show that 5-ALA-dosed glioma cells produce PpIX-positive EVs as compared 5-ALA-dosed human brain microvascular endothelial cells. We also found PpIX-positive EVs in the plasma from 5-ALA-dosed glioma-bearing mice compared to no rise in signal from the 5-ALA-dosed control mice. Finally, we show that plasma of patients with avidly fluorescent tumors under FGS contain circulating PpIX-positive EVs at levels significantly higher than their pre-dosing background and this rise in signal is positively correlated with enhancing tumor volumes (Figure 1).

    Conclusions: Our findings highlight the potential of plasma-derived PpIX-positive EV-based diagnostics for malignant gliomas, offering a novel liquid biopsy platform for confirming and monitoring tumor status.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy